Logo

Coya Therapeutics, Inc.

COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product cand… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.76

Price

0.00%

$0.00

Market Cap

$96.348m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-3920375.3%

EBITDA Margin

-3725080.7%

Net Profit Margin

-3528478.2%

Free Cash Flow Margin
Revenue

$423.450k

-88.1%

1y CAGR

-43.0%

3y CAGR

-32.2%

5y CAGR
Earnings

-$6.109b

-40953.8%

1y CAGR

-13668.4%

3y CAGR

-10288.9%

5y CAGR
EPS

-$1.24

-26.5%

1y CAGR

+10.9%

3y CAGR

-126.6%

5y CAGR
Book Value

$28.310b

$33.453b

Assets

$5.142b

Liabilities

-

Debt
Debt to Assets

0.0%

-

Debt to EBITDA
Free Cash Flow

-$8.609b

-83577.6%

1y CAGR

-27874.7%

3y CAGR

-20925.8%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases